Healthcare
Rhythm Pharmaceuticals, Inc.(RYTM)
Live Price
Offline$88.38
+0.82% today
1Y Change
+55.79%
Window
Jun 23, 2025 β Jun 18, 2026
- Market Cap
- $5.84B
- Revenue Growth
- +45.8%
- EPS Growth
- +28.3%
- Dividend Yield
- 0.0%
Coverage: 250 bars Β· Jun 23, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rhythm Pharmaceuticals, Inc. (RYTM) is a Healthcare stock with a market cap of $5.84B and listed on NASDAQ. The stock last traded around $88.38 and up 55.8% across the available one-year price window (Jun 23, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of +28.3%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS +28.3%, free cash flow -2.4% with operating margin -101.2% and ROIC -50.1%. Valuation already assumes a fairly strong business story at price/sales 30.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RYTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+45.8% vs +7.6% peer median
Operating Margin
Below sector median
-101.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +45.8% and EPS at +28.3%, with operating margin around -101.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | β | -0.4% | -3.0% | -9.3% |
2026 Feb 26, 2026 | +7.6% | -5.4% | -6.7% | -16.5% |
2025 Nov 4, 2025 | -13.9% | -5.3% | -4.9% | -0.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RYTM
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RYTM Max Drawdown
-35.54%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RYTM and SPY.
Company Overview
Rhythm Pharmaceuticals, Inc.
NASDAQ Global Market
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and AlstrΓΆm syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Leadership
- David Meeker
- IPO Date
- Oct 9, 2017
- Employees
- 283
- Street Address
- 222 Berkeley Street
- Mailing
- Boston, MA, 02116
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 264 4280
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 30.8
- Price/Book
- 41.2
Growth
- Revenue
- +45.8%
- EPS
- +28.3%
- Free Cash Flow
- -2.4%
Profitability
- Gross Margin
- 89.7%
- Operating Margin
- -101.2%
- Net Margin
- -103.6%
- ROE
- -179.1%
- ROIC
- -50.1%
Balance Sheet
- Debt/Equity
- 1.77
- Current Ratio
- 4.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.